Andros Pharmaceuticals Co.,Ltd (TPEX:6917)

Market Cap	1.56B +82.0%
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	45.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	435,246
Open	35.45
Previous Close	35.50
Day's Range	33.50 - 35.70
52-Week Range	18.35 - 45.95
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About TPEX:6917

Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6917

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error